Cellumen, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cellumen, Inc. - overview
Established
2004
Location
Pittsburgh, PA, US
Primary Industry
Pharmaceuticals
About
Based in Pennsylvania, US, and founded in 2004 by CEO Lansing Taylor, Cellumen, Inc. provides a cellular systems biology solution that provides accurate predictions of drug efficacy and safety. In August 2010, Cellumen was acquired by Apredica (Cyprotex). The company's flagship offering, CellCiphr, includes a suite of advanced reagents and assays designed to measure and manipulate cell function.
The products are used for profiling cellular models of disease and toxicity, enabling better lead generation, the identification of toxic liabilities early in the discovery process, and improved patient stratification.
Current Investors
Novitas Capital, Safeguard Scientifics, Pittsburgh Life Sciences Greenhouse
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.cellumen.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Cellumen, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member, Audit Committee Chairman | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.